Skip to main content

Advertisement

SpringerLink
Log in

Recent highlights of Chinese medicine for advanced lung cancer

  • Feature Article
  • Published:
Chinese Journal of Integrative Medicine Aims and scope Submit manuscript

Abstract

Owing to its unique superiority in improving quality of life and prolonging survival time among advanced lung cancer patients, Chinese medicine (CM) has, in recent years, received increased attentions worldwide. We utilized a bibliometric statistical method based on MEDLINE/GoPubMed to conduct a comprehensive analysis of the current application status of CM in lung cancer, by including annual and accumulated publications, origin distribution of countries and journals, and keywords with a higher frequency score. Then the relevant clinical trials and mechanistic studies were systematically summarized within the field according to research types. We have raised potential problems and provided potentially useful reference information that could guide similar studies in the future. The basic experimental results are highly consistent with clinical trials, leading us to conclude that CM can offer better overall therapeutic benefits when used in combination with routine Western medicine for patients with advanced lung cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Wood SL, Pernemalm M, Crosbie PA, Whetton AD. Molecular histology of lung cancer: from targets to treatments. Cancer Treat Rev 2015;41:361–375.

    Article  CAS  PubMed  Google Scholar 

  2. Chen YZ, Di LJ, Zhang SL, Chen MS, Sun H, Gao F, et al. The randomized, multicenter, controlled clinic trial for treating advanced non-small cell lung cancer with combined traditional Chinese medicine and vinorelbine plus cisplatin chemotherapy. Chin J Lung Cancer (Chin) 2008;11:441–444.

    CAS  Google Scholar 

  3. Perlikos F, Harrington KJ, Syrigos KN. Key molecular mechanisms in lung cancer invasion and metastasis: a comprehensive review. Crit Rev Oncol Hematol 2013;87:1–11.

    Article  PubMed  Google Scholar 

  4. Torre LA, Siegel RL, Jemal A. Lung cancer statistics. Adv Exp Med Biol 2016;893:1–19.

    Article  PubMed  Google Scholar 

  5. Bilsky MH, Laufer I, Matros E, Yamada J, Rusch VW. Advanced lung cancer: aggressive surgical therapy vertebral body involvement. Thorac Surg Clin 2014;24:423–431.

    Article  PubMed  Google Scholar 

  6. He XR, Li PP. Traditional Chinese medicine and palliative care for cancer. World Chin Med (Chin) 2014;9:839–844.

    Google Scholar 

  7. Gatenby RA. A change of strategy in the war on cancer. Nature 2009;459:508–509.

    Article  CAS  PubMed  Google Scholar 

  8. Lin HS, Li SQ, Piao BK. The efficacy evaluation method of Chinese medicine for advanced lung cancer treatment. Chin Cancer (Chin) 2000;9:354–355.

    Google Scholar 

  9. Doms A, Schroeder M. GoPubMed: exploring PubMed with the Gene Ontology. Nucleic Acids Res 2005;33:W783–W786.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Fajardo-Ortiz D, Duran L, Moreno L, Ochoa H, Castano VM. Mapping knowledge translation and innovation processes in cancer drug development: the case of liposomal doxorubicin. J Transl Med 2014;12:227.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Vanteru BC, Shaik JS, Yeasin M. Semantically linking and browsing PubMed abstracts with Gene Ontology. BMC Genomics 2008;9 Suppl 1:S10.

    Article  PubMed  PubMed Central  Google Scholar 

  12. Gompelmann D, Eberhardt R, Herth FJ. Advanced malignant lung disease: what the specialist can offer. Respiration 2011;82:111–123.

    Article  CAS  PubMed  Google Scholar 

  13. Chen H, Meng YH, Guo DA, Liu X, Liu JH, Hu LH. New cytotoxic 19-norbufadienolide and bufogargarizin isolated from Chan Su. Fitoterapia 2015;104:1–6.

    Article  CAS  PubMed  Google Scholar 

  14. Ning J, Yu ZL, Hu LH, Wang C, Huo XK, Deng S, et al. Characterization of phase I metabolism of resibufogenin and evaluation of the metabolic effects on its antitumor activity and toxicity. Drug Metab Dispos 2015;43:299–308.

    Article  PubMed  Google Scholar 

  15. Xu R, Xie HQ, Deng LL, Zhang JX, Yang FM, Liu JH, et al. A new bufadienolide with cytotoxic activity from the Chinese traditional drug Ch’an Su. Chin J Nat Med 2014;12:623–627.

    CAS  PubMed  Google Scholar 

  16. Sun T, Zhang Y, Shen Y, Hu K, Zuo M. A case of advanced lung cancer with malignant pericardial effusion treated by intrapericardial Cinobufacini injection instillation. BioScience Trends 2014;8:235–239.

    Article  PubMed  Google Scholar 

  17. Ishiura Y, Yamamoto H, Shiba Y, Terasaki Y, Ishida Y, Tanikawa F, et al. Effect of Japanese traditional medicine, TJ-41, on quality of life of patients with non-small cell lung cancer receiving outpatient chemotherapy. Cancer Chemother (Jpn) 2013;40:913–916.

    Google Scholar 

  18. Kamei T, Kumano H, Iwata K, Nariai Y, Matsumoto T. The effect of a traditional Chinese prescription for a case of lung carcinoma. J Altern Complement Med 2000;6:557–559.

    Article  CAS  PubMed  Google Scholar 

  19. Chen YZ, Li ZD, Zhou N, Sun H, Li PP. Longer overall survival in a patient with advanced non-small cell lung cancer treated with Chinese medicine and chemotherapy. Chin J Integr Med 2012;18:626–628.

    Article  PubMed  Google Scholar 

  20. Gao L, Li Q, Jiang M, Liu C, Song Z, Bao X, et al. Combined therapy of percutaneous cryoablation and traditional Chinese medicine can be a promising strategy for elderly or advanced lung cancer patients based on a retrospective clinical study. Cryobiology 2014;69:174–177.

    Article  PubMed  Google Scholar 

  21. Cheng JH, Liu WS, Li ZM, Wang ZG. A clinical study on global CM therapy in treating senile advanced non-small cell lung cancer. Chin J Integr Med 2007;13:269–274.

    Article  PubMed  Google Scholar 

  22. Xue NZ, Fang RM, Lin LZ. Application of response evaluation criteria of traditional Chinese medicine for solid tumor in advanced non-small cell lung cancer. Chin J Integr Med 2014;20:910–916.

    Article  PubMed  Google Scholar 

  23. Wu YL, Yang JJ, Lin JY, Huang YJ, Liao RQ, Huang YS, et al. Gefitinib target treatment in non-small cell lung cancer. Chin J Tuberc Respir Dis (Chin) 2007;30:98–102.

    Google Scholar 

  24. Yang XB, Wu WY, Long SQ, Deng H, Pan ZQ. Effect of gefitinib plus Chinese herbal medicine (CHM) in patients with advanced non-small-cell lung cancer: a retrospective casecontrol study. Complement Ther Med 2014;22:1010–1018.

    Article  PubMed  Google Scholar 

  25. Cao SF. An observational trial of Aidi Injection combined with chemotherapy for advanced lung cancer patients. Chin J Clin Oncol Rehabil (Chin) 2014;21:450–451.

    Google Scholar 

  26. Xu ZY, Jin CJ, Zhou CC, Wang ZQ, Zhou WD, Deng HB, et al. Treatment of advanced non-small-cell lung cancer with Chinese herbal medicine by stages combined with chemotherapy. J Cancer Res Clin Oncol 2011;137:1117–1122.

    Article  PubMed  Google Scholar 

  27. McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, et al. Astragalus-based Chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: metaanalysis of randomized trials. J Clin Oncol 2006;24:419–430.

    Article  CAS  PubMed  Google Scholar 

  28. Guo L, Bai SP, Zhao L, Wang XH. Astragalus polysaccharide injection integrated with vinorelbine and cisplatin for patients with advanced non-small cell lung cancer: effects on quality of life and survival. Med Oncol 2012;29:1656–1662.

    Article  CAS  PubMed  Google Scholar 

  29. Dong J, Su SY, Wang MY, Zhan Z. Shenqi fuzheng, an injection concocted from Chinese medicinal herbs, combined with platinum-based chemotherapy for advanced non-small cell lung cancer: a systematic review. J Exp Clin Cancer Res 2010;29:137.

    Article  PubMed  PubMed Central  Google Scholar 

  30. Garcia MK, McQuade J, Haddad R, Patel S, Lee R, Yang P, et al. Systematic review of acupuncture in cancer care: a synthesis of the evidence. J Clin Oncol 2013;31:952–960.

    Article  PubMed  PubMed Central  Google Scholar 

  31. Takeda K, Hida T, Sato T, Ando M, Seto T, Satouchi M, et al. Randomized phase III trial of platinum-doublet chemotherapy followed by gefitinib compared with continued platinum-doublet chemotherapy in Japanese patients with advanced non-smallcell lung cancer: results of a west Japan thoracic oncology group trial (WJTOG0203). J Clin Oncol 2010;28:753–760.

    Article  CAS  PubMed  Google Scholar 

  32. Liu ZL, Zhu WR, Zhou WC, Ying HF, Zheng L, Guo YB, et al. Traditional Chinese medicinal herbs combined with epidermal growth factor receptor tyrosine kinase inhibitor for advanced non-small cell lung cancer: a systematic review and meta-analysis. J Integr Med 2014;12:346–358.

    Article  PubMed  Google Scholar 

  33. Kin R, Kato S, Kaneto N, Sakurai H, Hayakawa Y, Li F, et al. Procyanidin C1 from Cinnamomi Cortex inhibits TGF-beta-induced epithelial-to-mesenchymal transition in the A549 lung cancer cell line. Int J Oncol 2013;43:1901–1906.

    CAS  PubMed  Google Scholar 

  34. Zhang L, Wu C, Zhang Y, Liu F, Wang X, Zhao M, et al. Comparison of efficacy and toxicity of traditional Chinese medicine (TCM) herbal mixture LQ and conventional chemotherapy on lung cancer metastasis and survival in mouse models. PLoS One 2014;9:e109814.

    Article  Google Scholar 

  35. Liu R, Zheng H, Li W, Guo Q, He S, Hirasaki Y, et al. Antitumor enhancement of Fei-Liu-Ping ointment in combination with celecoxib via cyclooxygenase-2-mediated lung metastatic inflammatory microenvironment in Lewis lung carcinoma xenograft mouse model. J Transl Med 2015;13:366.

    Article  PubMed  PubMed Central  Google Scholar 

  36. Zhou L, Pan Y, Xing Y, Gao H, Xie X, Yin D. Effects of Feijining Decoction on vascular endothelial growth factor protein expression and changes of T cell subsets in Lewis lung carcinoma-bearing mice. Biomed Rep 2015;3:403–407.

    PubMed  PubMed Central  Google Scholar 

  37. Tian JH, Shi ZM, Zhou ZY, Huang YS, Wang L. Effects of Feiji formula on lung cancer metastasis in mice. J Chin Integr Med (Chin) 2008;6:827–829.

    Article  Google Scholar 

  38. Du L, Chen YL, Chen M, Liu GJ, Yu J, Li YP. om CONSORT to GPP: an introduction to good publication practice. Acta editologica 2008;20:367–370.

    Google Scholar 

  39. Flower A, Witt C, Liu JP, Ulrich-Merzenich G, Yu H, Lewith G. Guidelines for randomised controlled trials investigating Chinese herbal medicine. J Ethnopharmacol 2012;140:550–554.

    Article  PubMed  Google Scholar 

  40. Gabler NB, Duan N, Vohra S, Kravitz RL. N-of-1 trials in the medical literature: a systematic review. Med Care 2011;49:761–768.

    Article  PubMed  Google Scholar 

  41. Chen X, Chen P. A comparison of four methods for the analysis of N-of-1 trials. PLoS One 2014;9:e87752.

    Article  Google Scholar 

  42. Nikles J, Mitchell GK, Schluter P, Good P, Hardy J, Rowett D, et al. Aggregating single patient (N-of-1) trials in populations where recruitment and retention was difficult: the case of palliative care. J Clin Epidemiol 2011;64:471–480.

    Article  PubMed  Google Scholar 

  43. Shamseer L, Sampson M, Bukutu C, Schmid CH, Nikles J, Tate R, et al. CONSORT extension for reporting N-of-1 trials (CENT) 2015: explanation and elaboration. J Clin Epidemiol 2016;76:18–46.

    Article  PubMed  Google Scholar 

  44. Huang H, Yang P, Xue J, Tang J, Ding L, Ma Y, et al. Evaluating the individualized treatment of traditional Chinese medicine: a pilot study of N-of-1 trials. Evid Based Complement Alternat Med 2014;2014:148730.

    PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Integration of Traditional Chinese and Western Medicine, Peking University School of Oncology, Peking University Cancer Hospital and Institute, Beijing, 100142, China

    Xi-ran He, Shu-yan Han & Ping-ping Li

Authors
  1. Xi-ran He
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Shu-yan Han
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Ping-ping Li
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Ping-ping Li.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

He, Xr., Han, Sy. & Li, Pp. Recent highlights of Chinese medicine for advanced lung cancer. Chin. J. Integr. Med. 23, 323–330 (2017). https://doi.org/10.1007/s11655-016-2736-2

Download citation

  • Received:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s11655-016-2736-2

Keywords

Search

Navigation